Scar Treatment and Management: Dermatological Approaches

Scar formation is an expected biological response to skin injury, yet the clinical spectrum of scarring — from flat, faded marks to raised, painful keloids — creates substantial functional and psychological burden for patients. Dermatologists apply a structured set of interventions ranging from topical silicone therapy to surgical revision, selected according to scar type, anatomical location, and patient-specific healing factors. This page covers the classification of scar types, the mechanisms behind established treatments, the clinical contexts in which each approach is applied, and the boundaries that define when referral or escalation is appropriate. For a broader orientation to dermatological care, the National Dermatology Authority home provides specialty context.

Definition and scope

A scar is the fibrous tissue that replaces normal skin architecture following dermal injury. The American Academy of Dermatology (AAD) classifies scars into four primary clinical categories that guide treatment selection:

1. Atrophic scars — depressed below the surrounding skin surface, subdivided into ice pick, boxcar, and rolling subtypes; most commonly associated with acne or varicella.
2. Hypertrophic scars — raised, firm, and erythematous but confined within the original wound boundary; more prevalent in areas of high skin tension such as the sternum and shoulders.
3. Keloid scars — raised fibrous overgrowths that extend beyond the original wound margin; more frequently observed in individuals with Fitzpatrick skin types IV through VI, a risk pattern documented in the AAD's clinical guidelines on keloids.
4. Contracture scars — result from thermal or chemical burns, drawing skin tightly across underlying structures and potentially restricting joint mobility.

The scope of scar management overlaps with both medical and cosmetic dermatology. The distinction matters for insurance coverage: the Centers for Medicare and Medicaid Services (CMS) defines coverage based on functional impairment rather than aesthetic concern, a regulatory framework detailed further at /regulatory-context-for-dermatology.

How it works

Scar treatment targets the underlying biology of aberrant wound healing. Normal scar maturation progresses through three phases — inflammatory, proliferative, and remodeling — over a period that can span 12 to 24 months. Treatments are designed to intervene at specific points in this cycle.

Silicone-based therapy is the first-line, evidence-supported intervention for hypertrophic scars and keloids. Silicone sheets and gels work by occluding the stratum corneum, increasing hydration, and modulating fibroblast activity. The British Association of Dermatologists (BAD) guidelines endorse silicone gel sheeting as a first-line prophylactic and treatment option, recommending application for a minimum of 12 hours per day over 3 to 6 months.

Intralesional corticosteroid injections suppress the inflammatory and proliferative phases by inhibiting collagen synthesis. Triamcinolone acetonide, administered at concentrations of 10 to 40 mg/mL at 4- to 6-week intervals, is the most widely used agent. Adverse effects include dermal atrophy and hypopigmentation, which are more clinically significant in skin of color — a consideration addressed in the AAD's position on dermatology and skin of color.

Pulsed-dye laser (PDL) targets oxyhemoglobin in scar vasculature at a wavelength of 585 to 595 nm, reducing erythema and pliability scores in hypertrophic scars. Fractionated ablative and non-ablative lasers are applied to atrophic acne scars, delivering controlled microcolumns of thermal injury to stimulate collagen remodeling. An overview of the broader clinical context for laser treatments in dermatology provides comparative procedure detail.

Surgical revision — including excision with primary closure, Z-plasty, or W-plasty — addresses scars where geometry or tension is the primary functional problem. Mohs reconstruction frequently confronts scar management decisions; the technique is covered in depth at Mohs surgery explained.

Common scenarios

Scar treatment is applied across a predictable set of clinical presentations:

• Post-acne atrophic scarring: Fractionated laser resurfacing and dermal fillers (including poly-L-lactic acid and hyaluronic acid products) are the primary interventions. The FDA has cleared specific devices for this indication under the 510(k) pathway for Class II medical devices.
• Surgical scars: Silicone sheeting initiated within the first 2 weeks of wound closure demonstrably reduces hypertrophic scar development compared to untreated wounds, according to a systematic review published in the Cochrane Database of Systematic Reviews.
• Keloids in high-tension anatomical zones: Combined therapy using intralesional triamcinolone plus 5-fluorouracil (5-FU) at a 4:1 ratio has shown recurrence rates lower than corticosteroid monotherapy in published randomized controlled trial data.
• Burn contractures: Physical and occupational therapy, pressure garments applied at 25 mmHg or above, and surgical release are coordinated through multidisciplinary teams; the American Burn Association (ABA) publishes practice guidelines governing this care pathway.
• Stretch marks (striae distensae): Classified separately from wound-derived scars, striae are treated with retinoids, fractional laser, and microneedling, though evidence for complete resolution remains limited in the published literature.

Decision boundaries

Selecting among these modalities depends on scar type, patient history, skin phototype, and risk tolerance. The following boundaries define when escalation or alternative approaches are warranted:

• Keloids with prior treatment failure require combination protocols — corticosteroid plus antimetabolite, or post-excision radiation — not monotherapy; recurrence after simple excision alone reaches 50 to 80 percent without adjuvant treatment (AAD clinical guidelines).
• Atrophic scars in Fitzpatrick types IV–VI carry elevated risk of post-inflammatory hyperpigmentation with ablative laser; non-ablative fractional devices and microneedling are preferred first-line options.
• Active inflammatory acne must be controlled before resurfacing procedures; treating atrophic scars in the presence of active disease risks new lesions forming in treated zones.
• Burn contractures affecting joint range of motion exceed the scope of outpatient dermatology and require surgical and rehabilitative specialist input under ABA guidelines.
• Immunosuppressed patients — including those on systemic biologics for psoriasis or atopic dermatitis — require modified wound-healing risk assessments before any invasive scar procedure.

The evidence base for scar management is graded using standard systems such as the Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence, which inform AAD clinical practice guidelines and help clinicians weigh intervention certainty against individual patient factors.

References

• American Academy of Dermatology (AAD) — Clinical Guidelines
• British Association of Dermatologists (BAD) — Scar Management Guidelines
• American Burn Association (ABA) — Practice Guidelines
• Centers for Medicare and Medicaid Services (CMS) — Coverage Determinations
• Cochrane Database of Systematic Reviews — Wound Management
• U.S. Food and Drug Administration (FDA) — 510(k) Premarket Notification Database
• Oxford Centre for Evidence-Based Medicine (OCEBM) — Levels of Evidence

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)